Close Menu

NEW YORK — Co-Diagnostics on Tuesday reported third quarter revenues of $21.8 million, compared with $41,434 in the year-ago period. The steep increase was primarily due to sales of its Logix Smart COVID-19 test for SARS-CoV-2.

Separately on Tuesday, the Salt Lake City-based company said that it received CE marks for two additional SARS-CoV-2 tests.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.